Scientists in Switzerland have developed a nanoreactor that can synthesise and release the antibiotic cephalexin, which is used to treat bacterial infections.
the drug dose required to effectively treat a patient would save money
and reduce side effects. To achieve this, one area of research is
focusing on using a ‘prodrug’ approach in which less toxic substrates,
or prodrugs, are given to a patient and are converted to the active drug
form by an enzyme only at a specific site. To maintain its catalytic
activity, the enzyme needs to be protected from the surrounding
environment, but also be accessible to the prodrug and able to release
the final active drug. More...